Skip to main content
Clinical Trials/NCT05569876
NCT05569876
Completed
Not Applicable

Vocal Biomarkers for the Detection and Prevention of Hypoglycemia (HypoVoice)

Insel Gruppe AG, University Hospital Bern1 site in 1 country7 target enrollmentNovember 11, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus
Sponsor
Insel Gruppe AG, University Hospital Bern
Enrollment
7
Locations
1
Primary Endpoint
Diagnostic accuracy of the HypoVoice approach to detect hypoglycemia based on voice data quantified as area under the receiver operating characteristic curve (AUROC)
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The HypoVoice study aims at identifying potential vocal biomarkers associated with hypoglycemia to pave the way towards a voice-based hypoglycemia detection approach.

Detailed Description

While hypoglycemia has been widely studied in medical research, studies assessing vocal changes associated with this state are limited. This study aims at collecting a data set labelled with the gold standard (blood glucose) to provide a solid basis for the identification of vocal biomarkers using machine learning. Additionally, physiological data are collected using wearable sensors to assess whether additional integration of vital signs (e.g. heart rate) enhances the performance of hypoglycemia detection.

Registry
clinicaltrials.gov
Start Date
November 11, 2022
End Date
January 31, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Written informed consent
  • Type 1 Diabetes mellitus as defined by WHO for at least 6 months
  • Aged 18 - 60 years
  • HbA1c ≤9.0 %
  • Functional insulin treatment with good knowledge of insulin self-management
  • Native language German or Swiss German
  • Use of continuous glucose monitoring (CGM) or flash glucose monitoring (FGM)

Exclusion Criteria

  • Incapacity to give informed consent
  • Contraindications to insulin aspart (NovoRapid®)
  • Total daily insulin dose \>2 IU/kg/day
  • Pregnancy, breast-feeding or lack of safe contraception
  • Active heart, lung, liver, gastrointestinal, renal or psychiatric disease
  • Pacemaker or implantable cardioverter defibrillator (ICD)
  • Epilepsy or history of seizure
  • Chronic neurological or ear-nose-and-throat (ENT) disease influencing voice or history of voice disorder
  • Illiteracy or dyslexia
  • Active smoking

Outcomes

Primary Outcomes

Diagnostic accuracy of the HypoVoice approach to detect hypoglycemia based on voice data quantified as area under the receiver operating characteristic curve (AUROC)

Time Frame: 4 hours

Voice data will be collected in eu- and hypoglycemia

Secondary Outcomes

  • Diagnostic accuracy of the HypoVoice approach to detect hypoglycemia based on voice and physiological data quantified as area under the receiver operating characteristic curve (AUROC)(4 hours)
  • Physiological parameters indicative of hypoglycemia(4 hours)
  • Voice parameters indicative of hypoglycemia(4 hours)

Study Sites (1)

Loading locations...

Similar Trials